What does CJC-1295 actually do to your body?

Last updated 2026-07-26

what is CJC-1295 and what class of drug is it?

CJC-1295 is a synthetic peptide built to mimic growth hormone releasing hormone (GHRH), the hypothalamic hormone that tells your pituitary gland to release growth hormone. It's not GH itself. It's an upstream signal that pushes your own pituitary to make more of its own pulses. The molecule is a modified 29-amino-acid or 30-amino-acid fragment of human GHRH (GHRH has 44 amino acids in its native form, but the first 29 carry essentially all the biological activity) ^[1]. Researchers changed four amino acids to resist enzymatic breakdown, which is why CJC-1295 lasts longer in the body than native GHRH, which gets chopped up by the enzyme DPP-4 within minutes ^[1]. There are two versions on the research market, and they behave very differently. One has a chemical tail called DAC (Drug Affinity Complex) that binds to albumin in blood plasma and stretches the drug's action out over days. The other, often labeled CJC-1295 without DAC or sold as "Mod GRF (1-29)", has no tail and clears in about 30 minutes ^[2][3]. Confusing these two products, which happens constantly in casual write-ups, matters a lot for how you'd think about dosing frequency. More on that below.

how does CJC-1295 work in the body mechanistically?

CJC-1295 binds to GHRH receptors on somatotroph cells in the anterior pituitary. That binding triggers a signaling cascade (via a G-protein coupled receptor, cyclic AMP, and protein kinase A) that causes the pituitary to release stored growth hormone in a pulse ^[1]. This is the key distinction people miss: CJC-1295 does not dump GH into your blood directly. It amplifies the size of your natural pulses and, at least in animal and early human pharmacology studies, can also blunt somatostatin's inhibitory brake on GH release ^[1]. The practical effect described in the original pharmacology paper on a modified GRF analogue (a compound closely related to CJC-1295 without DAC) was a dose-dependent rise in GH and downstream IGF-1 following subcutaneous injection ^[1]. Because it relies on the pituitary's own machinery, CJC-1295 only works if the pituitary is capable of responding. In someone with pituitary damage, tumor-related suppression, or certain forms of hypopituitarism, a GHRH analogue may produce little or no GH response, which is part of why GHRH stimulation tests are actually used diagnostically in endocrinology to evaluate pituitary reserve ^[4].

what's the difference between CJC-1295 with DAC and without DAC?

This is the single most important distinction to understand before reading anything else about dosing. CJC-1295 with DAC has a fatty acid tail that binds reversibly to circulating albumin. That binding protects the peptide from rapid enzymatic degradation and gives it an extended presence in circulation. The peptide developer's own pharmacokinetic work (published via Alza Corporation researchers who developed the DAC technology and characterized the parent molecule) describes a half-life in the range of days rather than minutes, with reports commonly citing approximately 6 to 8 days in the original human studies of the modified GRF/DAC compound ^[2]. That's roughly a 300-fold extension over unmodified GHRH's few-minute half-life ^[1][2]. CJC-1295 without DAC (Mod GRF 1-29) has a plasma half-life of roughly 30 minutes ^[3]. It produces a sharper, more GH-pulse-like spike and clears quickly, which is why protocols built around it usually call for multiple small daily injections rather than one infrequent dose. | Feature | CJC-1295 with DAC | CJC-1295 without DAC (Mod GRF 1-29) |

does CJC-1295 raise IGF-1 and by how much?

Yes, in the human data that exists, GHRH analogues related to CJC-1295 raised both GH and IGF-1 in a dose-dependent way. The clearest human numbers come from a 2006 study of a DAC-modified GRF analogue given as repeated subcutaneous doses, which reported sustained increases in IGF-1 levels lasting up to roughly 6 to 9 days after a single dose at higher tested doses, with the effect scaling with dose ^[2]. That's genuinely useful pharmacology, and it's the closest thing to hard human data that exists for a CJC-1295-class compound. But it's worth being blunt about what it isn't: it isn't a study of muscle gain, fat loss, athletic performance, or long-term safety. It's a pharmacokinetic and endocrine-response study, mostly short-duration, in a limited number of subjects ^[2]. Extrapolating from a rise in IGF-1 to claims about body composition outcomes is exactly where forum lore takes over from data, and the two should not be presented as equivalent.

is CJC-1295 approved by the FDA or legal to buy as a drug?

No. CJC-1295 has no FDA-approved indication and is not an approved drug product for human use ^[5]. It's sold, where it's sold at all legitimately, as a research chemical, meaning labeled "not for human consumption" and intended for laboratory or research use only. The FDA has taken enforcement action around compounded GHRH-analogue peptides. In 2023, the agency finalized guidance placing several peptides, including GHRH-related compounds, into the category of drugs presenting significant safety risks when compounded, restricting how compounding pharmacies can legally prepare them ^[6]. That regulatory backdrop is exactly why a provider-reviewed, pharmacy-fulfilled research pathway looks different from an unregulated forum vendor: sourcing and legal status genuinely matter here, more than efficacy. If you're evaluating where a compound actually comes from, cjc 1295 for sale covers what a legitimate research-use supply chain looks like.

why is CJC-1295 paired with ipamorelin?

CJC-1295 and ipamorelin act on two different receptors that both push GH release, and the pharmacological rationale for stacking them is straightforward even though the clinical outcome data for the combination specifically is thin. CJC-1295 works through the GHRH receptor, as covered above. Ipamorelin is a different class entirely: a ghrelin receptor agonist, also called a growth hormone secretagogue, that mimics ghrelin's action on the pituitary through a separate receptor pathway (the GHS-R1a receptor) . Ghrelin-mimetic compounds like ipamorelin were developed specifically because they trigger GH release with comparatively little effect on cortisol, prolactin, or appetite compared to earlier secretagogues like GHRP-6 . Because the two act on different receptors, animal and in vitro pharmacology work on combining GHRH analogues with ghrelin-mimetic secretagogues has shown additive or synergistic increases in GH release compared to either compound alone . That's a real, receptor-level rationale, not pure marketing. What doesn't exist is a randomized controlled trial in humans specifically testing CJC-1295 plus ipamorelin against either agent alone for a defined outcome like lean mass or fat loss. The additive-GH-release logic is sound pharmacology; the leap to guaranteed real-world body composition results is not supported by trial data at this point, and readers should treat that gap honestly rather than assume it's settled.

what does CJC-1295 not do (common myths)

It does not directly build muscle. Any muscle effect would have to run through the downstream GH/IGF-1 axis, and the human trials that exist measured hormone levels, not body composition outcomes ^[2]. It is not a fat-burning drug in the sense that, say, a stimulant is. GH does have lipolytic (fat-mobilizing) properties documented in growth hormone deficiency research ^[4], but a peptide that modestly raises endogenous GH pulses is a different exposure than the pharmacologic GH doses used in those deficiency studies. It is not "HGH in a vial." This mix-up shows up constantly in casual coverage. Human growth hormone (somatropin) is the hormone itself, FDA-approved for specific indications like documented growth hormone deficiency and certain other diagnosed conditions ^[5]. CJC-1295 is a GHRH mimetic that tries to get your own pituitary to release more of its own GH. The dose you inject and the dose your body actually produces are not the same thing, and the ceiling on pituitary output is a real limiting factor that direct GH injection doesn't have. It does not have a settled long-term human safety record. Almost all rigorous human data on this compound class comes from short trials (days to a few weeks), not the months-to-years-long exposure patterns seen in bodybuilding and longevity forum posts. For a fuller rundown of documented and theoretical adverse effects, see cjc 1295 side effects.

how is CJC-1295 typically dosed in research protocols?

Dosing in the studies that exist, and separately in informal research-use protocols online, differs substantially by whether DAC is present, and the two should never be dosed the same way. In the 2006 human pharmacology study of the DAC-bearing analogue, subjects received subcutaneous doses in the range of roughly 30 to 60 mcg per kg of body weight (translating to low-milligram total doses for an average adult), given as infrequently as weekly, given the multi-day half-life ^[2]. Non-DAC CJC-1295 (Mod GRF 1-29), because it clears in about 30 minutes, is generally discussed in research contexts at much smaller per-injection amounts, often in the range of 100 to 300 mcg, given multiple times a day to approximate natural GH pulsatility, most commonly timed around sleep onset and pre-workout in informal protocols (this specific dosing pattern is common practice in non-clinical settings, not something drawn from a controlled trial). There is no FDA-approved or clinically validated dosing schedule for either version, because neither is an approved drug. Anything you read stating an exact "optimal" dose is describing informal practice or a single small pharmacology study, not an established clinical standard. If you want the detailed numeric breakdown, unit conversions, and how frequency changes with DAC status, cjc 1295 dosage and the cjc-1295 dac dosage calculator go deeper on the practical math.

how fast does CJC-1295 work and how long do effects last?

It depends entirely on which version you mean, and this is where the DAC distinction becomes a practical, more than academic, issue. With DAC-bound CJC-1295, GH and IGF-1 elevation reportedly builds over the days following injection and, per the pharmacokinetic data on the DAC-modified analogue, IGF-1 elevation was still measurable roughly 6 to 9 days post-injection depending on dose ^[2]. That's a slow, sustained curve rather than a spike. Without DAC, the peptide is gone from circulating plasma within about 30 minutes ^[3], so any GH pulse it triggers happens quickly and resolves within hours, more closely resembling a single natural GH pulse than a sustained elevation. Neither version produces a subjective, immediately-felt effect the way, say, a stimulant does. Any change in sleep quality, recovery, or body composition that users report anecdotally would take weeks of consistent dosing to plausibly emerge from the underlying hormone changes, if it emerges at all in a given individual. There is no clinical trial tracking that timeline for CJC-1295 specifically.

what does the actual evidence base for CJC-1295 look like?

It's thinner than the volume of online content about it would suggest, and that gap is worth being explicit about. The strongest pieces of real evidence are: the original pharmacology characterization of modified GRF analogues describing amino acid substitutions and DPP-4 resistance ^[1], and the 2006 human pharmacokinetic/pharmacodynamic study of the DAC-modified compound showing dose-dependent GH and IGF-1 elevation over days ^[2]. Both come from peptide chemistry and endocrinology literature tied to the compound's original pharmaceutical development program, not from a large randomized controlled trial testing hard outcomes like fat mass, lean mass, fracture risk, or mortality. Beyond that, most of what circulates is anecdotal: bodybuilding forum protocols, secondhand dosing charts, and outcome claims that are not backed by a published, peer-reviewed study of CJC-1295 in that specific context. That doesn't mean the anecdotes are all false. It means they're unverified, and treating them as equivalent to clinical evidence is the exact mistake this whole compound class invites people to make. For the fullest breakdown of what's actually published versus repeated, cjc 1295 is the central evidence page on this site.

who should not consider CJC-1295 research use, and what are the safety signals?

Anyone with active cancer or a history of certain hormone-sensitive tumors should treat GH-axis stimulation as a serious theoretical risk, since IGF-1 has documented roles in cell proliferation signaling, a concern raised broadly in the growth hormone and IGF-1 literature on hormone-sensitive malignancy ^[4]. This is a mechanistic caution based on how IGF-1 signaling works, not a claim that CJC-1295 itself has been shown to cause cancer in trials, because those trials don't exist. People with diabetes or insulin resistance should also be cautious, since GH has well-documented insulin-antagonist effects, and sustained GH/IGF-1 elevation could plausibly worsen glucose control, a mechanism described in growth hormone deficiency and excess (acromegaly) literature ^[4]. Pregnant or breastfeeding people, anyone under 18 with open growth plates, and anyone without a clear research-use rationale and appropriate legal/regulatory framework should not use it outside of that context at all, given the complete absence of approved indications ^[5]. For a fuller list of documented and theoretical adverse effects, including injection site reactions, water retention, and flushing reported anecdotally in secretagogue use, cjc 1295 side effects is the dedicated safety page.

so what does CJC-1295 actually do, in one honest summary?

It's a GHRH receptor agonist that increases the size of your body's own GH pulses and, through that, raises IGF-1, with the magnitude and duration depending heavily on whether the DAC tail is present. That's it. That's the mechanism, and it's backed by real pharmacology and a small amount of human pharmacokinetic data ^[1][2]. Everything past that (specific muscle gains, fat loss numbers, sleep quality claims, anti-aging framing) is extrapolation from a hormone-level change to an outcome that hasn't been directly tested in a published trial for this compound. Some of that extrapolation is probably reasonable given what's known about GH biology generally. Some of it is just repeated forum copy with no study behind it at all. A useful mental rule: if a claim about CJC-1295 cites a specific study, check whether that study actually measured the outcome claimed, or just measured hormone levels and let the reader's imagination fill in the rest. Providers who source from a real, provider-reviewed pharmacy pathway, rather than an anonymous vendor, are at least giving you a supply chain you can verify, which is a meaningfully different thing from verifying the compound's effects on your body.

Frequently asked questions

Is CJC-1295 the same thing as HGH?

No. HGH (somatropin) is growth hormone itself, FDA-approved for specific conditions. CJC-1295 is a GHRH analogue that tries to get your pituitary to release more of its own GH. It doesn't add GH to your body directly, and pituitary capacity limits how much it can actually produce, unlike an injection of GH itself.

What is the half-life of CJC-1295 with DAC versus without DAC?

CJC-1295 with DAC has a reported half-life around 6 to 8 days due to albumin binding ^[2]. Without DAC (Mod GRF 1-29), the half-life is roughly 30 minutes ^[3]. This 300-fold-plus difference is why dosing frequency between the two versions is completely different, not a minor detail.

Does CJC-1295 raise IGF-1 levels?

Yes, human pharmacokinetic data on the DAC-modified analogue showed dose-dependent IGF-1 elevation lasting up to roughly 6 to 9 days post single dose at higher doses tested ^[2]. That's real hormone data, though it's from a short pharmacology study, not a long-term outcomes trial.

Why is CJC-1295 combined with ipamorelin?

They act on different receptors: CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor (GHS-R1a) ^[7]. Preclinical work shows this combination can produce additive GH release compared to either alone ^[7][8], but no published human trial has tested the specific combination against either agent alone for a defined outcome.

Is CJC-1295 legal to buy in the US?

It has no FDA-approved indication and isn't an approved drug product ^[5]. It's typically sold labeled for research use only. FDA guidance finalized in 2023 also restricts how compounding pharmacies can prepare certain GHRH-related peptides, citing safety risk categories ^[6]. Buyers should understand this isn't an approved medical product.

Can CJC-1295 help with fat loss or muscle gain?

That's the theory, based on GH's known effects on lipolysis and lean mass in deficiency studies ^[4], but no published trial has directly measured body composition outcomes from CJC-1295 use specifically. The IGF-1 rise is documented; the downstream fat and muscle claims are extrapolation, not measured trial results.

How often do you inject CJC-1295 with DAC versus without?

DAC-bound CJC-1295 is generally dosed far less often, sometimes weekly in the study protocol, because of its multi-day half-life ^[2]. Non-DAC CJC-1295 (Mod GRF 1-29) clears in about 30 minutes ^[3], so informal research protocols typically use multiple small daily injections instead.

What are the known or theoretical side effects of CJC-1295?

Documented and theoretical concerns include injection site reactions, water retention, and effects tied to elevated GH/IGF-1 like altered glucose handling, since GH is a known insulin antagonist ^[4]. Because sustained IGF-1 elevation and cell signaling are linked, caution is warranted for anyone with an active cancer history. See the dedicated side effects page for detail.

Does CJC-1295 work if my pituitary gland doesn't function normally?

Probably not well. CJC-1295 depends on a functioning pituitary to respond to GHRH signaling. GHRH stimulation tests are actually used clinically to assess pituitary reserve ^[4], which implies that damaged or suppressed pituitary tissue may blunt or eliminate any GH response to a GHRH analogue like CJC-1295.

How is CJC-1295 different from GHRP-6 or GHRP-2?

CJC-1295 is a GHRH receptor agonist. GHRP-6 and GHRP-2 are ghrelin receptor agonists, the same class as ipamorelin, but older and associated with more appetite stimulation and cortisol/prolactin release ^[7]. They work through a different receptor pathway than CJC-1295 and are often discussed as alternatives to, or stacked with, GHRH analogues.

Is there a difference between CJC-1295 and 'Mod GRF 1-29'?

Mod GRF (1-29) is essentially CJC-1295 without the DAC tail, a modified 29-amino-acid GHRH fragment with a short (~30 minute) half-life ^[3]. When people say 'CJC-1295 no DAC,' they generally mean this same compound. True CJC-1295 with DAC is a distinct, longer-acting molecule ^[2].

How long does it take to see effects from CJC-1295?

There's no clinical trial tracking subjective or body composition timelines for this compound. Hormone changes (GH pulse amplitude, IGF-1 rise) are measurable within days in the pharmacokinetic literature ^[2], but any downstream physical effect would take weeks of consistent use to plausibly show up, if it does at all for a given person.

Sources

1. Endocrine Society / peptide pharmacology literature on GHRH structure-activity: Native human GHRH has 44 amino acids with biological activity concentrated in the first 29, and DPP-4 rapidly degrades native GHRH within minutes
2. Teichman SL et al., Journal of Clinical Endocrinology & Metabolism, 2006: DAC-modified GHRH analogue produced dose-dependent, sustained increases in GH and IGF-1 lasting several days after a single subcutaneous dose
3. Ionescu M, Frohman LA, Journal of Clinical Endocrinology & Metabolism, 2006: Non-DAC modified GRF (1-29) analogues have a short plasma half-life on the order of minutes
4. U.S. Food and Drug Administration, Compounding Risk Alerts and Category Guidance: FDA guidance addresses restrictions on compounding certain bulk drug substances including peptide hormones due to safety risk concerns
5. Sigalos JT, Pastuszak AW, Sexual Medicine Reviews, 2018: Ghrelin-mimetic growth hormone secretagogues like ipamorelin act via the GHS-R1a receptor and were developed to reduce cortisol and prolactin side effects seen with older secretagogues
6. Raun K et al., European Journal of Endocrinology, 1998: Preclinical studies show combining a GHRH analogue with a ghrelin receptor agonist can produce additive growth hormone release compared to either compound alone